Clinical trial · Interventional
Effects of Telemonitoring in Quality of Life Amongst Cancer Patients
Effects in Quality of Life of a Telemonitoring Platform Amongst Patients With Cancer: A Randomized Trial
NCT06086990CI-TRIAL-00075810EQUALITEunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This interventional study aims to explore the potential of a smartphone app, Contigo, in enhancing the quality of life for patients with various cancers compared to standard care. The investigators will asses effects on quality of life, depressive symptoms, and appointment adherence.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Quality of Life | — | UNRESOLVED | — |
| Symptoms and Signs | — | UNRESOLVED | — |
| Telemedicine | — | UNRESOLVED | — |
| Telemonitoring | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Contigo Application | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Telemonitoring Platform
- description
- Patients assigned to the active intervention group will have access to a smartphone application named "Contigo." This application is designed to identify signs and symptoms of oncology drug toxicity while providing educational content. It equips patients with the necessary tools to manage typical clinical situations associated with the diagnosis and treatment of their disease.
- interventionNames
- Device: Contigo Application
- type
- NO_INTERVENTION
- label
- Traditional Follow-Up
- description
- Individuals designated to the traditional follow-up group will undergo standard care, including in-person check-ups as determined by their attending physician.
Primary outcomes (1)
- measure
- Quality of Life Scores
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (\>18 years old). * Recent histologically confirmed diagnosis (within the last 3 months) of bronchogenic, breast, gallbladder, gastric, colorectal, or prostate cancer in any of its forms. * Awaiting initiation of curative intent treatment for the disease using any modality (radiation therapy, chemotherapy, immunotherapy, etc.) at the UC-Christus Cancer Center. * Possession of a smartphone, regardless of its native operating system (iOS® or Android®). * Willingness to sign an informed consent form to participate in the study. Exclusion Criteria: * Any form of sensory impairment preventing app usage. * Cognitive impairment. * Psychiatric pathology hindering app usage. * Unwillingness to participate in the study. * Concurrent participation in another clinical trial addressing healthcare technologies.
References
Publications (4)
- BACKGROUNDSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID 33538338
- BACKGROUNDZarate V, Kind P, Valenzuela P, Vignau A, Olivares-Tirado P, Munoz A. Social valuation of EQ-5D health states: the Chilean case. Value Health. 2011 Dec;14(8):1135-41. doi: 10.1016/j.jval.2011.09.002. Epub 2011 Nov 6. PMID 22152184
- BACKGROUNDSprave T, Gkika E, Verma V, Grosu AL, Stoian R. Patient reported outcomes based on EQ-5D-5L questionnaires in head and neck cancer patients: a real-world study. BMC Cancer. 2022 Nov 29;22(1):1236. doi: 10.1186/s12885-022-10346-4. PMID 36447175
- DERIVEDMartinez F, Taramasco C, Espinoza M, Acevedo J, Goic C, Nervi B. Effects on Quality of Life of a Telemonitoring Platform amongst Patients with Cancer (EQUALITE): A Randomized Trial Protocol. Methods Protoc. 2024 Mar 15;7(2):24. doi: 10.3390/mps7020024. PMID 38525782